Novedades Mayo 2026

Enhanced independent discriminative performance of elevated lipoprotein(a) for cardiovascular outcomes in patients with diabetes: a comparative analysis of optimal cutoff values

Front Endocrinol (Lausanne). 2026 Apr 21:17:1795181. doi: 10.3389/fendo.2026.1795181. eCollection 2026.

Autores:

Song Wen 1 , Yanju He 1 , Xiucai Li 1 , Zhimin Xu 1 , Dan Liu 2 , Jiyu Li 3 , Ligang Zhou 1

Conclusión: Elevated Lp(a) levels are significantly associated with CVD and demonstrate strong discriminative utility, particularly in patients with DM. These findings suggest that more stringent Lp(a) thresholds may be warranted in the clinical management of diabetic patients to better identify individuals at high risk for cardiovascular outcomes.

Prevalence of Lipoprotein(a) Testing in Patients With Atherosclerotic Cardiovascular Disease Within a Large Australian Cardiology Network

Heart Lung Circ. 2026 May;35(5):606-619. doi: 10.1016/j.hlc.2025.11.017. Epub 2026 Apr 21.

Autores:

David Eccleston 1 , Enayet K Chowdhury 2 , Anna Williamson 3 , Meherin Rahman 4 , Catherine Sciascia 4 , Ravi Santani 4 , Renae Deans 2

Conclusión: The study revealed that Lp(a) testing is underutilised among patients with ASCVD in Australia despite recent guidelines recommending it. This emphasises the need to expand Lp(a) testing to improve health outcomes for high-risk patients.

10-Year Trends in Lipoprotein(a) Testing in Queensland and Australia: A Retrospective Analysis of Ordering Patterns

Heart Lung Circ. 2026 May;35(5):620-626. doi: 10.1016/j.hlc.2026.01.007. Epub 2026 Apr 20.

Autores:

Caroline A E Bachmeier 1 , Greg J Ward 2 , Ashley Arnott 2 , Behzad Kiani 3 , Andrew J Kassianos 4 , Michael M Page 5 , Karam M Kostner 6

Conclusión: Lp(a) testing has grown substantially in Queensland and Australia over the past decade, likely reflecting increased recognition of its causal role in cardiovascular disease, evolving guideline recommendations, test accessibility, and the emergence of novel therapies. However, overall testing remains limited. Broader implementation of guideline-based testing and greater clinician awareness will be critical to ensure timely identification of individuals who may benefit from available and emerging therapeutic strategies.

The role of lipoprotein(a) in coronary microvascular dysfunction: Mechanistic pathways, clinical evidence, and therapeutic perspectives

Life Sci. 2026 Jul 1:396:124371. doi: 10.1016/j.lfs.2026.124371. Epub 2026 Apr 3.

Autores:

Parmis Mansouri 1 , Reza Golchin Vafa 2

Lipoprotein(a) and acute coronary syndrome: Associations with sex, age and traditional cardiovascular risk factors

Rev Port Cardiol. 2026 May;45(5):217-226. doi: 10.1016/j.repc.2025.11.012. Epub 2026 Mar 26.

Autores:

Catarina Carrapa 1 , Marta Leite 2 , Francisca Saraiva 3 , Sílvia O Diaz 3 , António S Barros 3 , Inês Neves 2 , Marta Almeida 2 , Diogo Santos Ferreira 4 , Gualter Santos Silva 2 , Francisco Sampaio 4 , Eduardo Vilela 5 , Ricardo Fontes-Carvalho 4

Conclusión: Lp(a) levels showed a heterogeneous distribution and were not associated with traditional cardiovascular risk factors or other lipid parameters. This reinforces Lp(a) as an independent risk factor, supporting active screening in patients with ACS, particularly in women not affected by traditional cardiovascular risk factors.

The influence of lipoprotein(a) on coronary revascularization after percutaneous coronary intervention

Acta Cardiol. 2026 May;81(3):414-423. doi: 10.1080/00015385.2026.2643431. Epub 2026 Mar 17.

Autores:

Thitiphan Srikulmontri 1 2 , Suchanart Pantarote 3 , Narathorn Kulthamrongsri 4 , Phuuwadith Wattanachayakul 1 2 , Wasawat Vutthikraivit 5 , Aman Amanullah 2 6

Conclusión: Elevated Lp(a) levels were associated with a higher risk of repeat revascularization and TVR, with a non-significant trend towards increased TLR. Further studies are warranted to confirm these findings and explore the potential benefit of Lp(a)-lowering strategies.

Predictive Value of Lipoprotein(a) Combined with the Suita Score for High-Risk Plaque in Japanese Patients

J Atheroscler Thromb. 2026 May 1;33(5):566-577. doi: 10.5551/jat.65904. Epub 2025 Dec 11.

Autores:

Yudai Niwa 1 , Hiroyuki Naruse 2 , Hideki Kawai 1 , Eirin Sakaguchi 2 , Yuya Ishihara 2 , Hidekazu Hattori 2 , Komei Uehara 2 , Masaki Ito 2 , Shingo Yamada 3 , Akira Yamada 1 , Takashi Muramatsu 1 , Fumihiko Kitagawa 4 , Hiroshi Takahashi 1 , Junnichi Ishii 1 , Masayoshi Sarai 1 , Masanobu Yanase 1 , Yukio Ozaki 4 , Kuniaki Saito 5 , Hideo Izawa 1

Conclusión: The combinatorial value of assessing Lp(a) levels and Suita score may provide useful insight regarding Japanese patients undergoing CCTA for the prediction of HRP.

Impact of elevated lipoprotein(a) on epicardial coronary flow conductance and endoluminal atherosclerotic disease distribution

Cardiovasc Revasc Med. 2026 May:86:67-77. doi: 10.1016/j.carrev.2025.07.003. Epub 2025 Jul 8.

Autores:

Mick P L Renkens 1 , Tsung-Ying Tsai 2 , Pruthvi C Revaiah 3 , Shigetaka Kageyama 4 , Johan H C Reiber 5 , Robbert J de Winter 6 , Maik Grundeken 6 , Nick S Nurmohamed 7 , Erik Stroes 8 , Scot Garg 9 , Clemens von Birgelen 10 , Sjoerd Hofma 11 , Mohammad Alkhalil 12 , Liesbeth Rosseel 13 , Faisal Sharif 14 , Pieter C Smits 15 , Andreas Baumbach 16 , Yoshinobu Onuma 17 , Joanna J Wykrzykowska 18 , Patrick W Serruys 19

Conclusión: Elevated plasma levels of Lp(a) were associated with increased epicardial flow limitation and a more diffuse endoluminal disease pattern.